TISIDB

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cell projection Cell junction, synapse, synaptosome Cell projection, ruffle membrane Membrane; Peripheral membrane protein. Cytoplasmic vesicle membrane Peripheral membrane protein Cell junction, synapse Cytoplasm, cytosol Cell membrane Peripheral membrane protein Cytoplasmic side Note=Colocalizes with MAPT in axons. In primary neuronal cultures, present at a high level in presynaptic nerve terminals and in the cell body. Colocalizes with DNM1 at vesicular structures in the cell body and neurites (By similarity). Associates with membranes via its F-BAR domain.
Domain	PF00611 Fes/CIP4 PF14604 Variant SH3 domain
Function	Plays a role in the reorganization of the microtubule cytoskeleton via its interaction with MAPT; this decreases microtubule stability and inhibits MAPT-induced microtubule polymerization. Plays a role in cellular transport processes by recruiting DNM1, DNM2 and DNM3 to membranes. Plays a role in the reorganization of the actin cytoskeleton and in neuron morphogenesis via its interaction with COBL and WASL, and by recruiting COBL to the cell cortex. Plays a role in the regulation of neurite formation, neurite branching and the regulation of neurite length. Required for normal synaptic vesicle endocytosis; this process retrieves previously released neurotransmitters to accommodate multiple cycles of neurotransmission. Required for normal excitatory and inhibitory synaptic transmission (By similarity). Binds to membranes via its F-BAR domain and mediates membrane tubulation.

> Gene Ontology [ TOP ]
Biological Process	GO:0006898 receptor-mediated endocytosis GO:0007009 plasma membrane organization GO:0007015 actin filament organization GO:0010720 positive regulation of cell development GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0016358 dendrite development GO:0030100 regulation of endocytosis GO:0031346 positive regulation of cell projection organization GO:0036465 synaptic vesicle recycling GO:0045666 positive regulation of neuron differentiation GO:0045806 negative regulation of endocytosis GO:0048488 synaptic vesicle endocytosis GO:0048489 synaptic vesicle transport GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0051051 negative regulation of transport GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0051962 positive regulation of nervous system development GO:0060627 regulation of vesicle-mediated transport GO:0072583 clathrin-dependent endocytosis GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:0090002 establishment of protein localization to plasma membrane GO:0090150 establishment of protein localization to membrane GO:0097320 membrane tubulation GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0099003 vesicle-mediated transport in synapse GO:0099504 synaptic vesicle cycle GO:1900006 positive regulation of dendrite development GO:1990778 protein localization to cell periphery
Molecular Function	GO:0005543 phospholipid binding
Cellular Component	GO:0001726 ruffle GO:0005798 Golgi-associated vesicle GO:0030135 coated vesicle GO:0030137 COPI-coated vesicle GO:0030424 axon GO:0030659 cytoplasmic vesicle membrane GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0032587 ruffle membrane GO:0033267 axon part GO:0043209 myelin sheath GO:0043679 axon terminus GO:0044306 neuron projection terminus

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-8856828: Clathrin-mediated endocytosis R-HSA-199991: Membrane Trafficking R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PACSIN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PACSIN1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PACSIN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.185	0.443
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.418	0.415
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.013	0.975
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.206	0.807
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.171	0.896
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.689	0.632
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.362	0.605
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.159	0.272
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.624	0.564
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.04	0.934
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.45	0.467
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.648	0.00506

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PACSIN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PACSIN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PACSIN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PACSIN1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PACSIN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PACSIN1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PACSIN1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PACSIN1
Name	protein kinase C and casein kinase substrate in neurons 1
Aliases	SDPI; syndapin I; syndapin 1; syndapin-1; Protein kinase C and casein kinase substrate in neurons protein 1
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PACSIN1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PACSIN1